Milestone Pharmaceuticals Inc. (MIST): debt financing — Milestone Pharma raises $50M in convertible notes and $75M contingent royalty sale

Milestone Pharmaceuticals Inc.

Issued $50M principal of 6.0% Convertible Senior Notes due 2029 to RTW Investments.
Notes convertible at ~$5.23 per share (191.0548 shares per $1,000 principal).
Interest payable quarterly; PIK option for first 3 years; secured by substantially all assets.
Royalty Purchase Agreement: RTW to pay $75M for tiered royalties on U.S. etripamil sales post-FDA approval.
Proceeds support development of etripamil; notes mature March 31, 2029.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Milestone Pharmaceuticals Inc. incurred senior notes of $50 million principal amount with RTW Investments, LP and certain of its affiliates at 6.0% maturing March 31, 2029.

Instrument: senior notes
Principal: $50 million principal amount
Counterparty: RTW Investments, LP and certain of its affiliates
Rate: 6.0%
Maturity: March 31, 2029
Event: incurrence

Exact text from the filing

On March 29, 2023, the Company closed the transaction contemplated by the Note Purchase Agreement and issued and sold the $50 million principal amount of 6.0% Convertible Senior Notes due 2029

View on SEC.gov

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Milestone Pharmaceuticals Inc. incurred debt of $75.0 million with RTW Investments, LP and certain of its affiliates at tiered quarterly royalty payments.

Principal: $75.0 million
Counterparty: RTW Investments, LP and certain of its affiliates
Rate: tiered quarterly royalty payments
Event: incurrence

Exact text from the filing

nd a Note Purchase Agreement (the “Note Purchase Agreement”) with RTW Investments, LP and certain of its affiliates (collectively, “RTW”). Royalty Purchase Agreement Pursuant to the Royalty Purchase Agreement, RTW

View on SEC.gov

53 debt financings filed in the last 30 days. Browse all debt financings →

Milestone Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-039764

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.